Quantcast

Latest Aromatase inhibitor Stories

2011-08-18 15:13:00

THOUSAND OAKS, Calif., Aug. 18, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will present data from several Prolia® (denosumab) studies, including eight year efficacy and safety data from a Phase 2 extension study in women with postmenopausal osteoporosis with low bone mineral density (BMD), at the 2011 American Society for Bone and Mineral Research (ASBMR) Annual Meeting in San Diego, Calif. from Sept. 16-20, 2011. "The breadth of data being...

2011-08-17 06:38:45

(Ivanhoe Newswire) "“ Some women who naturally produce excess estrogen in their breasts are at an increased risk for developing breast cancer, according to this study conducted by researchers at Georgetown Lombardi Comprehensive Cancer Center. The investigators say their mice study shows that overproduction of aromatase, which converts testosterone into estrogen, in breast tissue is even more important in pushing breast cancer development than excess production of the estrogen receptor...

2011-08-15 12:05:51

Georgetown researchers discover in mice that a higher level of aromatase in breast tissue is more dangerous than excess production of estrogen receptors -- a finding that could impact prevention strategies Could some women who naturally produce excess aromatase in their breasts have an increased risk of developing breast cancer? Results of a new animal study suggests that may be the case, say researchers at Georgetown Lombardi Comprehensive Cancer Center, a part of Georgetown University...

2011-05-19 13:48:56

A subset of breast cancer patients who have tumors overexpressing a protein called the human epidermal growth factor receptor 2 (HER-2 positive) may benefit from a combination of targeted treatments and may not need chemotherapy, said researchers from the Lester and Sue Smith Breast Center at Baylor College of Medicine on behalf of the Translational Breast Cancer Research Consortium in an abstract released today by the American Society of Clinical Oncology. Dr. Jenny Chang, previously with...

2011-05-18 13:58:55

ER-positive breast cancer patients whose tumors have active protein Stat5 have increased likelihood of responding to anti-estrogen therapy Cancer researchers at the Kimmel Cancer Center at Jefferson and an international team of collaborators have discovered a biomarker in breast cancer that may help identify which women will respond to anti-estrogen therapy. The research appears in the May 16 online issue of the Journal of Clinical Oncology. Anti-estrogen drugs, most notably tamoxifen, are...

2011-04-05 21:19:48

Soy food consumption did not increase the risk of cancer recurrence or death among survivors of breast cancer, according to the results of a study presented at the AACR 102nd Annual Meeting 2011, held April 2-6. Researchers investigated the association between soy food intake and breast cancer outcomes among survivors, using data from a multi-institution collaborative study, the After Breast Cancer Pooling Project. "There has been widespread concern about the safety of soy food for women with...

2011-03-31 01:34:12

The estrogen inhibitor tamoxifen can prevent breast cancer from coming back in treated women whose tumors grow in the presence of the hormone. Unfortunately, tamoxifen's anti-tumor effect wanes in about half of these women, and now researchers from the Lester and Sue Smith Breast Center at Baylor College of Medicine think they know why. Low levels or loss of the protein Rho guanine disassociation inhibitor alpha or Rho GDI alpha can cause tumors to resist the effects of treatment with...

2011-03-23 15:06:00

THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced new long-term data showing that during the fourth and fifth years of Prolia® (denosumab) treatment, postmenopausal women with osteoporosis receiving Prolia continued with further, statistically significant, year-over-year increases in lumbar spine and total hip bone mineral density (BMD), a key measurement of bone strength. The overall adverse event profile was similar for the...

2011-03-23 15:05:00

THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia® (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis. Adherence to treatment, which includes both compliance (a measure of how well patients follow directions for taking...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related